title: Chronotherapeutically Modulated Pulsatile System of Valsartan Nanocrystals-an In Vitro and In Vivo Evaluation.
abstract: The objective was to improve the dissolution of valsartan by developing valsartan nanocrystals and design a pulsed release system for the chronotherapy of hypertension. Valsartan nanocrystals were prepared by sonication-anti-solvent precipitation method and lyophilized to obtain dry powder. Nanocrystals were directly compressed to minitablets and coated to achieve pulsatile valsartan release. Pharmacokinetic profiles of optimized and commercial formulations were compared in rabbit model. The mean particle size and PDI of the optimized nanocrystal batch V4 was reported as 211 nm and 0.117, respectively. DSC and PXRD analysis confirmed the crystalline nature of valsartan in nanocrystals. The dissolution extent of valsartan was markedly enhanced with both nanocrystals and minitablets as compared to pure valsartan irrespective of pH of the medium. Core minitablet V4F containing 5% w/w polyplasdone XL showed quickest release of valsartan, over 90% within 15 min. Coated formulation CV4F showed two spikes in release profile after successive lag times of 235 and 390 min. The pharmacokinetic study revealed that the bioavailability of optimized formulation (72.90%) was significantly higher than the commercial Diovan tablet (30.18%). The accelerated stability studies showed no significant changes in physicochemical properties, release behavior, and bioavialability of CV4F formulation. The formulation was successfully designed to achieve enhanced bioavailability and dual pulsatile release. Bedtime dosing will more efficiently control the circadian spikes of hypertension in the morning.
authors.affiliation: Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India, 700032.
authors.forename: Nikhil
authors.initials: N
authors.lastname: Biswas
authors.affiliation: Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India, 700032. ketousetuoju@yahoo.in.
authors.forename: Ketousetuo
authors.initials: K
authors.lastname: Kuotsu
mesh_terms: D000818:Animals; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical / Q000379:methods; D004337:Drug Carriers / Q000737:chemistry; D008297:Male; D053758:Nanoparticles / Q000737:chemistry* / Q000378:metabolism; D010316:Particle Size; D011208:Powders / Q000737:chemistry / Q000378:metabolism; D011817:Rabbits; D012995:Solubility; D013607:Tablets / Q000737:chemistry / Q000378:metabolism; D000068756:Valsartan / Q000737:chemistry* / Q000378:metabolism
chemical_list: D004337:Drug Carriers; D011208:Powders; D013607:Tablets; D000068756:Valsartan
keywords: HPLC method validation; anti-solvent precipitation; chronotherapy; pharmacokinetic parameters; valsartan nanocrystals